바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.63 No.4
Citation Share

The Efficacy of Added Montelukast in Persistent Asthmatics Who Were Not Not Completely Controlled on Inhaled Corticosteroids and Inhaled Long-acting β2-agonists

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2007, v.63 no.4, pp.337-345












& (2007). The Efficacy of Added Montelukast in Persistent Asthmatics Who Were Not Not Completely Controlled on Inhaled Corticosteroids and Inhaled Long-acting β2-agonists. Tuberculosis & Respiratory Diseases, 63(4), 337-345.
  • Downloaded
  • Viewed
PDF Download

Abstract

Backgrounds: Although glucocorticoids are one of the most potent anti-inflammatory agents, they have limited effect on cysteinyl leukotriene biosynthesis. In addition, the response to inhaled corticosteroids (ICS) and inhaled long-acting β2-agonists (LABA) combination therapy in moderate to severe persistent asthmatics varies. Additional therapy with leukotriene receptor antagonists (LTRA) in patients with moderate to severe asthma suboptimally controlled with ICS and LABA combination therapy would be complementary to asthma control. Methods: One hundred and ninety eight asthmatics entered a 2 month, open-label descriptive study. Patients suffering from persistent asthma and suboptimally controlled on a combination therapy of fluticasone/salmeterol or budesonide/ formoterol were given montelukast 10 mg daily as an add-on therapy. The level of asthma control was assessed using the Asthma Control Questionnaire (ACQ) including FEV1 % predicted at the baseline and after a 2-month treatment with montelukast. A global evaluation of the treatment was also made by the patients and physicians. Results: The mean ACQ score decreased significantly on montelukast (11.5±5.4 at baseline vs. 6.7±5.0), with a significant improvement in all individual symptom scores (p<0.01). The FEV1 % predicted values did not show any significant change. 59.9% of patients and 59.4% of physicians reported global improvement in their asthma (κ=0.85). Conclusion: These results suggest that the addition of montelukast in patients with persistent asthma that is suboptimally contolled by combination therapy of ICS and LABA might confer complementary effects on asthma control. (Tuberc Respir Dis 2007; 63: 337-345)

keywords
Asthma control, Inhaled glucocorticosteroid, Long-acting inhaled β2-agonist, Montelukast., Asthma control, Inhaled glucocorticosteroid, Long-acting inhaled β2-agonist, Montelukast.

Reference

1.

(2003) Chapter 66. Asthma pathogenesis, Philadelphia: Mosby, Inc

2.

(2003) Global initiative for asthma (GINA),

3.

(2002) Significant variability in response to inhaled corticosteroids for persistent asthma,

4.

(2003) Chapter 52. Glucocorticoids, Philadelphia: Mosby, Inc

5.

(2001) The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma,

6.

Leukotrienes and other products of the 5-lipoxygenase pathway,

7.

The role of leukotrienes in inflammation,

8.

(1999) Leulkotriene-receptor antagonists,

9.

(1999) Treatment of asthma with drugs modifying the leukotriene pathway,

10.

(2000) Effect of leukotriene receptor antagonists therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials,

11.

(2003) Effects of montelukast on surrogate inflammatory markers in corticosteroid treated asthmatics,

12.

(2005) Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting β2-agonists: addition of montelukast in an open-label pilot study,

13.

(1999) Development and validation of a questionnaire to measure asthma control,

14.

(2004) Can guideline-defined asthma control be achieved? The gaining optimal asthma control study,

15.

(2002) Impact of montelukast on symptoms in mild-to-moderate persistent asthma and exercise-induced asthma: results of the asthma survey,

16.

(2003) Motelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomized, comparative trial,

17.

(2006) Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma,

18.

(2007) Combination therapy with a long acting β-agonist and a leukotriene antagonist in moderate asthma,

19.

(2004) The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy